Rapid Discovery Of Antagonistic Human/Cyno CD200R1 Llama VHH Nanobodies Using Single B Cell Technology

By Nicole Polewaczyk, Dan Luo, Damon Jian, Ke Zou, Hsun-Hui Yang, Molly Smith, Yadong Yu, Lucy Qi, Vincent Pai, Samuel Hinman, Julie Perreau, Margaret Wong Ho, Brian A. Zabel, and Christine L. Hsieh

Nanobodies are a growing modality in antibody therapeutics, with FDA-approved treatments driving demand for VHH discovery. Their small size and typically longer CDR3 enable targeting challenging epitopes in solid tumors, overcoming limitations of larger antibodies.

Here, we used single B cell antibody discovery to rapidly identify a diverse set of potent, high-affinity, neutralizing VHH from immunized llamas against CD200R1, an emerging therapeutic immune checkpoint target.